Arthneeti
AP

Aarti Pharmalabs Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Aarti Pharmalabs Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹817
Market cap₹6.2K Cr
P/E35.0
Updated23 Aug 2026
Read4 min read

The short version

CDMO segment expected to grow 30%-40% this year, aiming for Rs. CDMO segment is expected to grow at 30%-40% annually this year, aiming for Rs.

From Aarti Pharmalabs Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • CDMO segment expected to grow 30%-40% this year, aiming for Rs. 800-1,000 crores revenue in 3-4 years (Page 17, 9).
  • Overall CDMO growth target of Rs. 800-1,000 crores by FY '29 (Page 9).
  • Xanthine business capacity expanding from 5,000 to 9,000 tons, targeting Rs. 1,000+ crores revenue in 2-3 years with 80%-90% utilization and 50% of sales to beverages and regulated customers (Pages 10-11).
  • API segment expected to grow 10%-15% this year and maintain reasonable growth levels, with capacity expansions and de-bottlenecking underway (Page 17).
  • Additional capacities, such as Atali plant, to drive growth starting H2 FY ’26 onwards with risk-mitigated multi-site manufacturing capabilities (Page 15, 17).
  • EBITDA growth expected to align with topline expansion, with CDMO margins highest among segments (Page 15).

Profitability & Margins

See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- Brownfield expansion to increase Xanthine derivatives capacity from 5,000 MT to 9,000 MT per annum; commissioning to be done in a phased manner across H2 FY '26. - Greenfield project at Atali, Gujarat nearing completion; mechanical completion of Phase-1 achieved; commercial production to commence towards end of Q2 FY '26. - Additional caffeine capacity addition planned in second half of this year. - Next year to see higher capacities enabling production of more products. - Ongoing efforts on de-bottlenecking of API lines and capacity additions to support growth in base business. - Investments in enhancing CDMO capabilities including cyanation, continuous manufacturing, cryogenic reactions, hydrogenation, and HPAPIs (anti-cancer products). - Future expansion blocks planned every two years subject to occupancy levels. Overall, these capex plans aim to drive growth in CDMO, Xanthine, and API segments while improving margins and supporting long-term strategic objectives.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1Accretion Pha.
Rev 1Mar 2
2OneSource Specialty Pharma Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company currently has an order book guiding CDMO sales growth of 35%-40% for the year.
  • There are 60 ongoing active CDMO projects: 33 in commercial stages and 27 in different stages of development.
  • The management is confident about achieving Rs. 800 crore to Rs. 1,000 crore revenue from the CDMO segment by FY '28 or FY '29, a 3-4 year timeline.
  • Growth drivers include both existing commercial molecules and a robust underdevelopment pipeline.
  • The final commercial success depends on customer approvals and market performance of the products.
  • The company has seeded about 60 projects and is actively working on multiple stages of processing.

Aarti Pharmalabs Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹583 Cr, net profit ₹61 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Aarti Pharmalabs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Sai Life Sciences Ltd (Q1 FY26)

    Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth). Key concall takeaways from Sai…

  • Cipla Ltd (Q1 FY26)

    One Africa business grew 11% YoY, with continued focus on expansion. Key concall takeaways from Cipla's Q1 FY26 earnings call — and how it ranks against sector…

  • Anthem Biosciences Ltd (Q1 FY26)

    Capacity utilization in custom synthesis is around 70%, with expansions ongoing, indicating potential for further revenue growth. Key concall takeaways from…

  • Senores Pharmaceuticals Ltd (Q1 FY26)

    . Key concall takeaways from Senores Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Aarti Pharmalabs Ltd Q1 FY26 results?

CDMO segment expected to grow 30%-40% this year, aiming for Rs. CDMO segment is expected to grow at 30%-40% annually this year, aiming for Rs.

What is Aarti Pharmalabs Ltd share price analysis?

Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aarti Pharmalabs Ltd planning capital expenditure?

Brownfield expansion to increase Xanthine derivatives capacity from 5,000 MT to 9,000 MT per annum; commissioning to be done in a phased manner across H2 FY '26.

Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.